Coalition for Healthcare Communication Executive Director John Kamp said in a commentary posted Monday on the Coalition's Website that if the forthcoming decision by the U.S. Supreme Court in FTC v. Actavis regarding AndroGel is decided against the pharmaceuticals industry, it "could create a significant bottom line hit to our business. A decision against pharma would further shorten the patent protection period on many branded drugs." Kamp provided a summary of the important issues at stake in the case, for which oral arguments were heard on March 25. Despite the legal challenges, "don't count the industry out yet," Kamp said. Read more.

Full Story:

Related Summaries